Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Lin Shen et al.|Annals of Oncology|2019Cited by 475
The role of the kynurenine pathway in cardiovascular diseaseYuehang Yang, Jiawei Shi, Xing Liu et al.|Frontiers in Cardiovascular Medicine|2024Cited by 46